

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
-------------------------	----------------

NATURE OF CONVEYANCE:	Amendment to Assignment
------------------------------	-------------------------

CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Premium Pharmaceuticals Pty Limited		01/29/2004	CORPORATION: AUSTRALIA

RECEIVING PARTY DATA	
Name:	Bioline Developments Limited
Street Address:	Flat F, 30th Floor, Block 4
City:	Broadview Garden, Tsing Yi, N.T.
State/Country:	HONG KONG
Entity Type:	CORPORATION: HONG KONG

PROPERTY NUMBERS Total: 1		
Property Type	Number	Word Mark
Registration Number:	2821427	SORBOLENE

CORRESPONDENCE DATA	
Fax Number:	(908)722-0755
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	908-722-0700
Email:	ipdept@nmmlaw.com
Correspondent Name:	Davy E. Zoneraich
Address Line 1:	P.O. Box 1018
Address Line 4:	Somerville, NEW JERSEY 08876

ATTORNEY DOCKET NUMBER:	103611-001B
--------------------------------	-------------

DOMESTIC REPRESENTATIVE	
Name:	
Address Line 1:	
Address Line 2:	
Address Line 3:	

CH \$40.00 2821427

Address Line 4:

NAME OF SUBMITTER:

Davy E. Zoneraich

Signature:

/dez/

Date:

06/15/2007

Total Attachments: 2

source=assnprembioamend#page1.tif

source=assnprembioamend#page2.tif

RECORDATION FORM COVER SHEET

TRADEMARKS / SERVICE MARKS ONLY

To the Director of the U. S. Patent and Trademark Office: Please record the attached original documents or the new address(es) below.

1. Name of conveying party(ies):

Premium Pharmaceuticals Pty Limited

- Individual(s)
- General Partnership
- Corporation-State: **Australia**
- Other
- Association
- Limited Partnership

Citizenship (see guidelines)

Additional names(s) of conveying party(ies) Yes No

3. Nature of conveyance/Execution Date(s):

Execution Date: **January 29, 2004**

- Assignment
- Security Agreement
- Other **Amendment to Assignment**
- Merger
- Change of Name

2. Name and address of receiving party(ies):

Additional names, addresses, or citizenship attached? Yes No

Name: **Bioline Developments Limited**

Internal Address:

Address:

Street Address: **Flat F, 30th Floor, Block 4**

City: **Broadview Garden, Tsing Yi, N.T.**

State:

Country: **Hong Kong**

ZIP:

- Association Citizenship
- General Partnership Citizenship
- Limited Partnership Citizenship
- Corporation Citizenship **Hong Kong**
- Other

If assignee is not domiciled in the United States, a domestic representative designation is attached: Yes No
(Designations must be a separate document from

4. Application number(s) or registration numbers(s) and identification or description of the Trademark/Service Mark:

A. Trademark / Service Mark Application No.(s)

B. Trademark / Service Mark Registration No.(s)

2,821,427

Additional sheet(s) attached? Yes No

C. Identification or Description of Trademark(s)/Service Mark(s) (and Filing Date if Application or Registration Number is unknown):

5. Name & address of party to whom correspondence concerning document should be mailed:

Name: **Davy E. Zoneraich**

Internal Address:

Street Address:

P.O. Box 1018

City: **Somerville**

State: **NJ**

Zip: **08876**

Phone Number: **908-722-0700**

Fax Number: **908-722-0755**

Email Address: **ipdept@nmmlaw.com**

6. Total number of applications and registrations involved:

1

7. Total fee (37 CFR 2.6(b)(6) & 3.41) \$ **40.00**

- Authorized to be charged by credit card
- Authorized to be charged to deposit account
- Enclosed

8. Payment Information:

a. Credit Card Last 4 Numbers _____
Expiration Date _____

b. Deposit Account Number **14-1263**

Authorized User Name **Norris,McLaughlin & Marcus**

9. Signature:


Signature

Davy E. Zoneraich

Name of Person Signing

June 15, 2007

Date

Total number of pages including cover sheet, attachments, and document:

2

AMENDMENT NUMBER ONE TO DEED OF ASSIGNMENT

This AMENDMENT (the "Amendment") is made as of January 29, 2004, by and between Premium Pharmaceuticals PTY Limited of 127 Darling Street, Blamain in the state of New South Wales, Australia ("Premium"), and Bioline Developments Limited of Flat F, 30th Floor, Block 4, Broadview Garden, Tsing Yi, N.T., Hong Kong ("Bioline").

PREAMBLE

Pursuant to the August 2, 2001 Deed of Assignment of Trademark between Premium and Bioline ("Deed"), the parties have entered into an agreement where Premium assigned to Bioline all its rights, title and interest in certain trademarks set out in Schedules 1 and 2 to the Deed.

In order to address certain errors in the Deed concerning the identification of the particulars of the assignment of United States trademark rights, title and interest, the parties have agreed to enter into and be bound by the terms and conditions set forth in this Amendment.

AGREEMENT


1. Construction. All terms not otherwise defined in this Amendment shall have the meanings set forth in the Deed. Except as set forth herein, the Deed shall remain unaffected by execution of this Amendment. All terms and conditions set forth in this Amendment shall be considered to have been in existence as of, and shall be retroactive to, the date execution of the Deed.

2. Identification of United States Trademark Application for SORBOLENE in Schedule 2 and in the United States Trademark Assignment attached to Schedule 2. In Schedule 2 and in the United States Trademark Assignment attached to Schedule 2, the reference to U.S. application number "75/684544" shall be replaced by reference to U.S. application number -- 75/742,625--.


3. Effective date of assignment of all rights, title and interest to the SORBOLENE trademark in the United States. The Deed and the United States Trademark Assignment attached to Schedule 2 of the Deed shall further recite the following: "The effective date of the assignment of all rights, title and interest to the SORBOLENE trademark in the United States, including U.S. trademark application number 75/742,625 for SORBOLENE, shall be August 12, 2003."

4. Counterparts. This Amendment may be executed in several counterparts, each of which shall be deemed an original, and all of which taken together shall constitute one and the same instrument.

PREMIUM PHARMACEUTICALS PTY
LIMITED

By: 
Title: MANAGING DIRECTOR

BIOLINE DEVELOPMENTS LIMITED

By: 
Title: DIRECTOR